Jul. 24 at 7:11 PM
$IKNA NASDAQ Equity Corporate Actions Alert #2025 - 393
Information Regarding the Business Combination of Ikena Oncology, Inc. (IKNA) and Inmagene Biopharmaceuticals
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-393
The business combination of Ikena Oncology, Inc. (IKNA) and Inmagene Biopharmaceuticals is expected to close Friday, July 25, 2025. Following the completion of the business combination, the company's Common stock (IMA) will undergo a name, symbol, and CUSIP number change along with a one-for-twelve (1-12) reverse stock split. The combined company will list on the Nasdaq Capital Market. These actions will become effective on Monday, July 28, 2025.
Further, pre-merger shareholders of record on July 24, 2025 will receive one (1) non-transferable Contingent Value Right (CVR) for each share held, payable on July 25, 2025. The CVR distribution will not be quoted EX. Subject to closing.